METTL3 Protein (m6A Methyltransferase)

Structure

METTL3 (Methyltransferase Like 3) is the catalytic core component of the N6-methyladenosine (m6A) methyltransferase complex. The protein contains an N-terminal region involved in protein-protein interactions and a C-terminal methyltransferase domain that harbors the catalytic activity. The methyltransferase domain adopts a canonical Rossmann fold characteristic of S-adenosylmethionine (SAM)-dependent methyltransferases, with a conserved DVX 8CX2CX3X motif coordinating the binding of the methyl donor SAM. METTL3 forms a stable heterodimer with METTL14, which serves as the substrate recognition subunit, while WTAP (Wilms’ Tumor 1-Associated Protein) facilitates nuclear localization and complex assembly. Structural studies reveal that METTL3 contains a zinc-binding domain (ZFD) at the N-terminus that contributes to RNA binding specificity. The METTL3-METTL14 heterodimer recognizes a consensus DRACH motif (D=A/G/U, R=A/G, A, C, H=A/C/U) in RNA substrates, with the catalytic site positioned to methylate adenine residues within single-stranded RNA regions.

Normal Function in the Nervous System

METTL3 and the m6A methyltransferase complex play critical roles in regulating RNA metabolism in the nervous system:

• m6A RNA Modification: Catalyzes N6-methyladenosine (m6A) formation, the most abundant internal modification in mRNA, affecting RNA splicing, stability, translation, and subcellular localization

• Synaptic Transmission: m6A modification regulates the translation of synaptic proteins and controls synaptic plasticity; Mettl3 knockout in neurons leads to impaired long-term memory formation

• Neurodevelopment: Essential for cortical neurogenesis; deletion in neural progenitor cells causes delayed neuronal differentiation and migration defects

• Axon Guidance: Regulates the translation of axon guidance molecule mRNAs during development

• Glial Function: Important for oligodendrocyte differentiation and myelination; m6A regulates myelin gene expression

In the brain, METTL3 is expressed in neurons and glial cells, with particularly high expression in the hippocampus and cerebral cortex. The m6A modification is dynamically regulated during brain development and in response to neuronal activity, suggesting important roles in learning and memory.

Role in Neurodegeneration

Alzheimer’s Disease

METTL3 dysfunction has been implicated in Alzheimer’s disease pathogenesis. Studies show altered m6A levels in AD brain tissue, with some reports indicating increased m6A modification of specific transcripts. METTL3-mediated methylation affects the expression and splicing of amyloid processing genes, tau kinase and phosphatase transcripts, and synaptic plasticity-related mRNAs. The m6A reader YTHDF2, which mediates mRNA decay, shows altered expression in AD brains, suggesting that disrupted m6A homeostasis contributes to AD pathogenesis through impaired RNA metabolism.

Parkinson’s Disease

In Parkinson’s disease, METTL3 and m6A modification regulate the translation of genes involved in mitochondrial function, autophagy, and alpha-synuclein metabolism. Alpha-synuclein mRNA contains m6A modifications that affect its translation and aggregation propensity. Studies in PD models show that METTL3 knockdown protects against dopaminergic neuron loss, while METTL3 overexpression exacerbates pathology, suggesting that dysregulated m6A methylation contributes to PD progression.

Amyotrophic Lateral Sclerosis (ALS)

METTL3 and m6A modifications are altered in ALS, affecting the metabolism of transcripts encoding RNA-binding proteins (TDP-43, FUS) and stress response genes. ALS-associated mutations in FUS and TDP-43 affect m6A regulation, and the m6A pathway influences the splicing of ALS-relevant genes. Therapeutic targeting of the m6A pathway is being explored as a potential intervention.

Intellectual Disability and Neurodevelopmental Disorders

De novo pathogenic variants in METTL3 cause a neurodevelopmental syndrome characterized by intellectual disability, speech delay, and behavioral abnormalities. These findings underscore the essential role of m6A methylation in human brain development and cognitive function. The m6A modification is critical for neuronal gene expression programs that underlie learning and memory.

Therapeutic Targeting

The m6A methylation pathway represents a promising therapeutic target for neurodegenerative diseases:

• Small Molecule Inhibitors: STM2457 is a selective METTL3 catalytic inhibitor that has shown promise in cancer models and is being explored for neurological applications

• Antisense Oligonucleotides: ASOs targeting specific m6A-modified transcripts could restore normal RNA metabolism

• Reader Protein Modulators: Drugs targeting m6A reader proteins (YTHDF1-3, YTHDC1-2) could modulate translation and stability of disease-relevant transcripts

• Gene Therapy: AAV-mediated expression of METTL3 or modulators could restore m6A homeostasis

See Also

• Alzheimer’s Disease

• Parkinson’s Disease

External Links

• PubMed

• KEGG Pathways